Cytokinetics, Incorporated (NASDAQ:CYTK) has received a consensus recommendation of “Moderate Buy” from analysts covering the company. According to data from MarketBeat, a total of twenty-one analysts have evaluated the stock, with seventeen issuing buy ratings, three holding recommendations, and one sell rating.
The average price target for Cytokinetics stands at $88.83, based on reports from brokerages over the past year. Recent analyst assessments have varied, with some firms adjusting their price targets. For instance, Citizens JMP raised its target from $88.00 to $96.00 and reported a “market outperform” rating on February 25, 2025. Barclays initiated coverage on the stock with an “overweight” rating and a target price of $87.00 on January 28, 2025.
Needham & Company LLC adjusted its price target from $84.00 to $85.00, maintaining a “buy” rating, while Royal Bank of Canada increased its target from $95.00 to $101.00 with an “outperform” rating on February 20, 2025. HC Wainwright also raised its price target significantly from $120.00 to $136.00, affirming a “buy” rating on December 22, 2024.
Institutional Investors Increase Holdings
Recent activity among institutional investors indicates growing confidence in Cytokinetics. EverSource Wealth Advisors LLC has dramatically increased its stake by 723.7% in the second quarter, now owning 766 shares valued at approximately $25,000 after acquiring an additional 673 shares. Other notable investments include Kemnay Advisory Services Inc. and Kestra Advisory Services LLC, both acquiring new stakes valued around $27,000 and $29,000, respectively.
Quarry LP also entered the fray with a new stake valued at approximately $30,000, while TD Waterhouse Canada Inc. added a position valued at around $32,000. These movements suggest that institutional investors are increasingly optimistic about the company’s future prospects.
Cytokinetics’ Recent Performance
On February 24, 2025, Cytokinetics reported its quarterly earnings, disclosing an earnings per share (EPS) of ($1.50), falling short of the consensus estimate of ($1.48) by $0.02. The company achieved revenue of $17.76 million, exceeding analyst expectations of $8.02 million. This revenue reflects a year-over-year increase of 4.9%, compared to the same quarter last year when the company reported an EPS of ($1.26).
As of the latest data, shares of Cytokinetics opened at $62.19. The firm has a market capitalization of $7.66 billion, a price-to-earnings (P/E) ratio of -9.52, and a beta of 0.56. Over the past year, its share price has fluctuated between a low of $29.31 and a high of $70.98. Analysts project an EPS of ($5.24) for the current fiscal year, indicating expectations of continued challenges in profitability.
Founded in 1998 and headquartered in South San Francisco, California, Cytokinetics is a late-stage biopharmaceutical company focused on developing innovative small-molecule therapeutics that enhance muscle function. The company’s primary program, omecamtiv mecarbil, is currently being evaluated for heart failure treatment by improving cardiac muscle contractility. As it continues its research, Cytokinetics aims to address critical medical needs in muscle function disorders.
